Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with vestibular schwannoma and/or meningioma diagnosed by MRI where surgical resection has been selected as treatment.~* Patients diagnosed with NF2 must meet Manchester Criteria.~* Age \> 18 years of age~* Prior biologic therapy, chemotherapy, surgery or radiation is permitted.~* At the time of screening, the patient must have normal organ and marrow function.~* Eastern Cooperative Oncology Group/World Health Organization (ECOG/WHO) performance status of 0-1.~* Patients must be able to swallow capsules.~* Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial.~* Tumor type will be confirmed by a neuropathologist.~* Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL prior to starting AR-42.~* The patient must be willing to comply with fertility requirements~Exclusion Criteria:~* Pregnant women are excluded from this study because the potential for teratogenic or abortifacient effects of AR-42 are not known. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with AR-42, breastfeeding should be discontinued if the mother is treated with AR-42.~* Pediatric patients are excluded from the phase 0 study as the effects of AR-42 are not known on children and there is no potential direct benefit to them.~* Patients with malabsorption or any other condition that in the opinion of the principal investigator could cause difficulty in absorption of drug.~* Patients requiring chronic corticosteroids (dose equivalent \> 20mg prednisolone).~* Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug.~* Patients with a currently active second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, increase patient risk, or confound data interpretation.~* Patients with a mean QTcB \> 450 msec in males and \> 470 msec in females.~* Patients with long QT syndrome.~* Patients who are being treated for an active infection.~* Patients receiving the following concomitant medications:~  * Any other anti-neoplastic chemotherapy or biologic therapy during the study~ * Concomitant radiotherapy~ * Concomitant HDAC inhibitors (e.g. valproic acid) as class-specific adverse reactions may be additive~ * Use of granulocyte colony-stimulating factors including G-CSF, pegylated G-CSF or GM-CSF should follow ASCO guidelines for patients receiving anti-cancer therapy.~ * Drugs associated with QT/QTc prolongation (see Appendix A)~* Patients who are receiving concurrent anti-neoplastic therapy.~* Any other medical condition, including mental illness or substance abuse, deemed by the principal investigator to likely interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.~* Patients with significant cardiovascular disease, including a myocardial infarction or unstable angina within 6 months or unstable cardiac arrhythmias are not eligible for the study.~* Known HIV infection, as their immunosuppressive conditions may complicate potential pancytopenias seen with HDAC inhibitors and complicate evaluation of drug effect.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AR-42 Administration (Type: EXPERIMENTAL): AR-42 will be administered three times per week beginning 3 weeks prior to surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).